PMID- 30740946 OWN - NLM STAT- MEDLINE DCOM- 20190809 LR - 20190809 IS - 1899-5276 (Print) IS - 1899-5276 (Linking) VI - 28 IP - 5 DP - 2019 May TI - Matrix metalloproteinase-3 levels in relation to disease activity and radiological progression in rheumatoid arthritis. PG - 665-670 LID - 10.17219/acem/94065 [doi] AB - BACKGROUND: Rheumatoid arthritis (RA) is a chronic inflammatory and systemic disease of unknown etiology that primarily affects synovial joints and involves progressive destruction around the joints. Inflammation starting in the joint synovium causes the destruction of cartilage, bone and other adjacent tissues with pannus formation. OBJECTIVES: The aim of this study was to evaluate serum matrix metalloproteinase-3 (MMP-3) levels and their clinical and radiological significance in patients with rheumatoid arthritis. MATERIAL AND METHODS: The study included 59 patients with RA and 30 healthy controls. Serum MMP-3 levels were measured using the enzyme-linked immunosorbent assay (ELISA) method. Patients with a Disease Activity Score 28 (DAS28) 3.2 indicated patients with moderate/high disease activity. Additionally, the patients were divided into 2 groups in terms of disease duration: early RA (disease duration /=2 years). Functional disability was evaluated using the Health Assessment Questionnaire (HAQ) and Nottingham Health Profile (NHP). Radiographs were scored using modified Larsen scoring. RESULTS: Serum MMP-3 levels in patients with RA were significantly higher than in controls (p = 0.001). Serum MMP-3 levels were correlated with laboratory and clinical parameters of disease activity, including erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), DAS28, and HAQ score; the exceptions were rheumatoid factor (RF) and cyclic citrullinated peptides (CCP). The serum MMP-3 levels of RA patients with moderate/high disease activity were found to be significantly higher than those of the patients with low disease activity (p < 0.001). However, MMP-3 levels were found to be similar in both established and early RA patients (p = 0.927). Additionally, the modified Larsen scores, which indicate structural damage, correlated significantly with serum MMP-3 levels (p = 0.001). CONCLUSIONS: These results indicate that serum MMP-3 levels may be used as an indicator for structural damage such as erosions in the early stages of the disease, and to monitor disease activity. FAU - Tuncer, Turkan AU - Tuncer T AD - Department of Physical Medicine and Rehabilitation, Faculty of Medicine, Firat University, Elazig, Turkey. FAU - Kaya, Arzu AU - Kaya A AD - Department of Physical Medicine and Rehabilitation, Faculty of Medicine, Firat University, Elazig, Turkey. FAU - Gulkesen, Arif AU - Gulkesen A AD - Department of Physical Medicine and Rehabilitation, Faculty of Medicine, Firat University, Elazig, Turkey. FAU - Kal, Gul Ayden AU - Kal GA AD - Department of Physical Medicine and Rehabilitation, Elazig Training and Research Hospital, Turkey. FAU - Kaman, Dilara AU - Kaman D AD - Department of Biochemistry and Clinical Biochemistry School of Medicine, Firat University, Elazig, Turkey. FAU - Akgol, Gurkan AU - Akgol G AD - Department of Physical Medicine and Rehabilitation, Faculty of Medicine, Firat University, Elazig, Turkey. LA - eng PT - Journal Article PL - Poland TA - Adv Clin Exp Med JT - Advances in clinical and experimental medicine : official organ Wroclaw Medical University JID - 101138582 RN - 0 (Biomarkers) RN - 9009-79-4 (Rheumatoid Factor) RN - EC 3.4.24.17 (MMP3 protein, human) RN - EC 3.4.24.17 (Matrix Metalloproteinase 3) MH - Arthritis, Rheumatoid/blood/*diagnostic imaging MH - Biomarkers/blood MH - Blood Sedimentation MH - Case-Control Studies MH - Disease Progression MH - Enzyme-Linked Immunosorbent Assay MH - Humans MH - Matrix Metalloproteinase 3/*blood/metabolism MH - Predictive Value of Tests MH - *Radiography MH - Rheumatoid Factor OTO - NOTNLM OT - disease activity OT - matrix metalloproteinase 3 OT - modified Larsen score OT - rheumatoid arthritis EDAT- 2019/02/12 06:00 MHDA- 2019/08/10 06:00 CRDT- 2019/02/12 06:00 PHST- 2019/02/12 06:00 [pubmed] PHST- 2019/08/10 06:00 [medline] PHST- 2019/02/12 06:00 [entrez] AID - 10.17219/acem/94065 [doi] PST - ppublish SO - Adv Clin Exp Med. 2019 May;28(5):665-670. doi: 10.17219/acem/94065.